Summit Therapeutics

Yahoo Finance • 4 days ago

Why Summit Therapeutics Inc. (SMMT) Soared Last Week?

We recently published a list of 10 Firms Defy Market Slump, Record Double-Digit Gains Last Week. In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other firms that defied the market... Full story

Yahoo Finance • 4 days ago

3 Magnificent Stocks That Could Double or More by 2030

When the stock market is as turbulent as it is these days, it's easy to forget the times when things are decidedly more cheery. However, sell-offs present great opportunities to buy stocks with significant upside potential. Three Motley F... Full story

Yahoo Finance • 4 days ago

Why Summit Therapeutics Inc. (SMMT) Surged On Friday?

We recently published a list of Gold, Biopharma Firms Dominate Friday’s 10 Top Performing Stocks. In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other Friday’s top performing sto... Full story

Yahoo Finance • 16 days ago

Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.

Building a retirement portfolio of $1 million or more is within reach for many Americans. The primary things you'll need are time and money to invest. Do you want $1 million in retirement? There's no guarantee that you'll be able to achie... Full story

Yahoo Finance • 26 days ago

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MIAMI, March 21, 2025--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 147,500 shares of common s... Full story

Yahoo Finance • 2 months ago

Q4 2024 Summit Therapeutics Inc Earnings Call

Participants Dave Gancarz; Chief Business & Strategy Officer; Summit Therapeutics Inc Robert Duggan; Executive Chairman of the Board, Co-Chief Executive Officer; Summit Therapeutics Inc Mahkam Zanganeh; President, Co-Chief Executive Off... Full story

Yahoo Finance • 3 months ago

Is Summit Therapeutics Inc. (SMMT) the Unstoppable Stock to Buy in 2025?

We recently published a list of 10 Unstoppable Stocks to Buy in 2025. In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other unstoppable stocks to buy in 2025. As per the recent e... Full story

Yahoo Finance • 3 months ago

Why Summit Therapeutics Stock Is Jumping Today

Shares of Summit Therapeutics(NASDAQ: SMMT) had jumped 14.3% at 11:31 a.m. ET on Tuesday. The nice gain came after reports that H.C. Wainwright analyst Mitchell Kapoor maintained a "buy" rating for the stock with a 12-month price target of... Full story

Yahoo Finance • 6 months ago

Summit Therapeutics Inc. (SMMT): Hedge Funds Are Bullish On This NASDAQ Stock Right Now

We recently compiled a list of the 10 Best Performing NASDAQ Stocks in 2024.In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against the other great performing NASDAQ stocks. Market Expec... Full story

Yahoo Finance • 7 months ago

Is Summit Therapeutics Inc. (SMMT) the Best Performing Stock in 2024?

We recently compiled a list of the 10 Best Performing Stocks in 2024.In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against the other great-performing stocks. Dow Breaks Record The Dow... Full story

Yahoo Finance • 7 months ago

This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy?

Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of artificial intelligence, and its revenue, earnings, and stock price continue to grow incredibly fast. Nvidia's shares... Full story

Yahoo Finance • 7 months ago

Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study

Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study Tuesday, Merck & Co Inc (NYSE:MRK) released topline data from the HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in patients with locally... Full story

Yahoo Finance • 7 months ago

Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half

Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half Sunday, Summit Therapeutics Inc. (NASDAQ:SMMT) released data from the primary analysis of the Phase 3 HARMON... Full story

Yahoo Finance • 9 months ago

Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab

Five Year Collaboration Intended to Advance PD-1 / VEGF Bispecific in Several Solid Tumors across Multiple Clinical Trials MIAMI & HOUSTON, July 25, 2024--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "C... Full story

Yahoo Finance • 10 months ago

3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street

Never ignore the power of momentum. Sometimes the fastest-moving objects are the ones that keep on racing ahead. That could be the case with a select group of stocks that have delivered tremendous gains this year. These three stocks have... Full story

Yahoo Finance • 11 months ago

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy

Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Benefit: PFS Hazard Ratio of 0.46 For Subset of Patients Previously Receiving 3rd Generation EGFR-TKI: PFS Hazard Ratio... Full story

Yahoo Finance • last year

Insiders Are Buying These 11 Penny Stocks

In this article, we will take a detailed look at Insiders Are Buying These 11 Penny Stocks. For a quick overview of such stocks, read our article Insiders Are Buying These 5 Penny Stocks. US stock market started the second quarter of 2024... Full story

Yahoo Finance • last year

Q4 2023 Summit Therapeutics Inc Earnings Call

Participants David Ganzarcz; Chief Business & Strategy Officer; Summit Therapeutics Inc Bob Duggan; CEO & Chairman; Summit Therapeutics Inc Maky Zanganeh; CEO & President‍; Summit Therapeutics Inc Ankur Dhingra; Chief Financial Officer... Full story

Yahoo Finance • last year

Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024

Conference Call to be Held at 9:00am ET MIAMI, Fla., February 14, 2024--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its fourth quarter and full year 20... Full story

Yahoo Finance • 2 years ago

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023

First US Patient Treated in Ivonescimab Clinical Trial after Closing Agreement; $500M Raised in Fully-Subscribed Rights Offering MENLO PARK, Calif., May 11, 2023--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," o... Full story